119 related articles for article (PubMed ID: 38290444)
1. Characteristics and Influencing Factors of Coagulation Dysfunction Caused by Cefoperazone/Sulbactam.
Zeng J; Zou M; Min M; Xu M
Altern Ther Health Med; 2024 Jan; ():. PubMed ID: 38290444
[TBL] [Abstract][Full Text] [Related]
2. A Comparison of Coagulation Function in Patients Receiving Aspirin and Cefoperazone-Sulbactam With and Without Vitamin K
Wu S; Wu G; Wu H
Clin Ther; 2021 Dec; 43(12):e335-e345. PubMed ID: 34819242
[TBL] [Abstract][Full Text] [Related]
3. Effect of Cefoperazone/Sulbactam on Blood Coagulation Function in Infected Emergency Department Patients and the Necessity of Vitamin K1 (VK1) Preventive Intervention: A Single-Center, Retrospective Analysis.
Shao X; Ren Y; Xie N; Fan K; Sun H; Lu J; Wei J; Tian X
Med Sci Monit; 2023 Jun; 29():e939203. PubMed ID: 37271979
[TBL] [Abstract][Full Text] [Related]
4. Cefoperazone-sulbactam and risk of coagulation disorders or bleeding: a retrospective cohort study.
Wang W; Liu Y; Yu C; Tan J; Xiong W; Dong D; Li S; Zhang R; Li J; Wu Y; Zong Z; Su N; Zou K; Wu G; Sun X
Expert Opin Drug Saf; 2020 Mar; 19(3):339-347. PubMed ID: 31914329
[No Abstract] [Full Text] [Related]
5. Comparison of bleeding risk and hypofibrinogenemia-associated risk factors between tigecycline with cefoperazone/sulbactam therapy and other tigecycline-based combination therapies.
Zhang L; Cai X; Peng F; Tian S; Wu X; Li Y; Guo J
Front Pharmacol; 2023; 14():1182644. PubMed ID: 37351509
[No Abstract] [Full Text] [Related]
6. Development and validation of a nomogram for predicting cefoperazone/sulbactam-induced hypoprothrombinaemia in Hospitalized adult patients.
Bai H; Li H; Nie X; Yao Y; Han X; Wang J; Peng L
PLoS One; 2023; 18(9):e0291658. PubMed ID: 37733780
[TBL] [Abstract][Full Text] [Related]
7. Risk Factors for Cefoperazone/Sulbactam-Induced Coagulation Disorder.
Miao W; Guo J; Cheng H; Zhao Q
Infect Drug Resist; 2023; 16():6277-6284. PubMed ID: 37766881
[TBL] [Abstract][Full Text] [Related]
8. Optimal Dose of Cefoperazone-Sulbactam for Acute Bacterial Infection in Patients with Chronic Kidney Disease.
Chao CM; Lai CC; Lee CH; Tang HJ
Antibiotics (Basel); 2022 Apr; 11(5):. PubMed ID: 35625254
[TBL] [Abstract][Full Text] [Related]
9. Risk-factor analysis and predictive-model development of acute kidney injury in inpatients administered cefoperazone-sulbactam sodium and mezlocillin-sulbactam sodium: a single-center retrospective study.
Zhang R; Gao L; Chen P; Liu W; Huang X; Li X
Front Pharmacol; 2023; 14():1170987. PubMed ID: 37361226
[No Abstract] [Full Text] [Related]
10. Clinical characteristics and risk factors of tigecycline-associated hypofibrinogenaemia in critically ill patients.
Hu J; Xiao YH; Zheng Y; Lai YX; Fang XL; Fang Q
Eur J Clin Pharmacol; 2020 Jul; 76(7):913-922. PubMed ID: 32355990
[TBL] [Abstract][Full Text] [Related]
11. Cefoperazone/sulbactam therapeutic drug monitoring in patients with liver cirrhosis: Potential factors affecting the pharmacokinetic/pharmacodynamic target attainment.
Dong Y; Li Y; Zhang Y; Zhang T; Zhu L; Dong Y; Wang T
Basic Clin Pharmacol Toxicol; 2019 Oct; 125(4):353-359. PubMed ID: 31056857
[TBL] [Abstract][Full Text] [Related]
12. Comparison of antibiotic-associated diarrhea caused by cefoperazone/sulbactam or piperacillin/tazobactam in neurosurgery patients.
Chen Y; Xiang Q; Liu L
J Int Med Res; 2021 May; 49(5):3000605211019661. PubMed ID: 34057835
[TBL] [Abstract][Full Text] [Related]
13. The Investigation on Nosocomial Infection of Acinetobacter baumannii and the Clinical Analysis of Sequential Therapy of Cefoperazone/Sulbactam Sodium for Intracranial Infection.
Xiong Z; Zeng D; Shen S; Han Z
Comput Math Methods Med; 2022; 2022():4525892. PubMed ID: 36017154
[TBL] [Abstract][Full Text] [Related]
14. Effect of impaired renal function on the pharmacokinetics of coadministered cefoperazone and sulbactam.
Rho JP; Castle S; Smith K; Bawdon RE; Norman DC
J Antimicrob Chemother; 1992 Jun; 29(6):701-9. PubMed ID: 1506350
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness and Safety of Generic Formulation of Cefoperazone/Sulbactam (Bacticep®) in Treatment of Infections at Siriraj Hospital.
Koomanachai P; Tongsai S; Thamlikitkul V
J Med Assoc Thai; 2016 Jan; 99(1):8-14. PubMed ID: 27455819
[TBL] [Abstract][Full Text] [Related]
16. Observation of clinical efficacy of the cefoperazone/sulbactam anti-infective regimen in the treatment of multidrug-resistant Acinetobacter baumannii lung infection.
Wang Q; Huang M; Zhou S
J Clin Pharm Ther; 2022 Jul; 47(7):1020-1027. PubMed ID: 35285526
[TBL] [Abstract][Full Text] [Related]
17. A retrospective analysis of carbapenem-resistant Acinetobacter baumannii-mediated nosocomial pneumonia and the in vitro therapeutic benefit of cefoperazone/sulbactam.
Xia J; Zhang D; Xu Y; Gong M; Zhou Y; Fang X
Int J Infect Dis; 2014 Jun; 23():90-3. PubMed ID: 24726664
[TBL] [Abstract][Full Text] [Related]
18. Comparison of Tigecycline or Cefoperazone/Sulbactam therapy for bloodstream infection due to Carbapenem-resistant
Niu T; Luo Q; Li Y; Zhou Y; Yu W; Xiao Y
Antimicrob Resist Infect Control; 2019; 8():52. PubMed ID: 30886705
[TBL] [Abstract][Full Text] [Related]
19. Pharmacovigilance of cutaneous adverse drug reactions in associations with drugs and medical conditions: a retrospective study of hospitalized patients.
Zheng L; Jin HB; Guan YY; Yang J
BMC Pharmacol Toxicol; 2022 Aug; 23(1):62. PubMed ID: 35948985
[TBL] [Abstract][Full Text] [Related]
20. Tracking Cefoperazone/Sulbactam Resistance Development In vivo in A. baumannii Isolated from a Patient with Hospital-Acquired Pneumonia by Whole-Genome Sequencing.
Liu X; Zheng H; Zhang W; Shen Z; Zhao M; Chen Y; Sun L; Shi J; Zhang J
Front Microbiol; 2016; 7():1268. PubMed ID: 27594850
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
